A small molecule Plk4 inhibitor, CFI-400945 (an ATP competitive inhibitor), was tested in patient-derived mice xenografts (against a range of cancer types) and significantly reduced tumour growth and increased overall survival [30,109,110]. This evidence concerns the gene PLK4 and cancer.